Why brand teams miss commercial growth (and what the data reveals)
In atopic dermatitis, 23% of new patient starts come from HCPs that brand teams either deprioritize...
The therapeutic market that you know is shaped by the healthcare data that you can see. But when critical medical, specialty, clinical or longitudinal signals are absent from that view, the picture (and the decisions based on it) is less clear. ...
In atopic dermatitis, 23% of new patient starts come from HCPs that brand teams either deprioritize...
We put the newest HealthVerity eXOs capabilities to the test on one of the most-watched questions...
Know what closed payer claims can reveal about patient journeys, treatment persistence and the...
Most teams planning a total cost of care or burden of illness study assume the cost data will be...
Know what open claims data can reveal and when it’s the right starting point for research Adding...
Know what others can’t about scaling AI Artificial intelligence is already embedded in how life...
The therapeutic market that you know is shaped by the healthcare data that you can see. But when...
Most life sciences teams don't have a data shortage. They have blind spots such as patients who...
Stress-testing a research question Every technology vendor claims their product works. The question...
The social determinants of health (SDoH) are a key component of understanding and delivering better...
In atopic dermatitis, 23% of new patient starts come from HCPs that brand teams either deprioritize or don’t have in their data at all. One in three top-decile prescribers in that same market saw zero new patient starts over a 22-month stretch. In ob...